Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

New RUP3 receptor modulators and their use claimed by Arena

Sep. 10, 2004

Utility of pramlintide demonstrated in recent diabetes trials

Sep. 10, 2004

Activity of BLX-1002 assessed in vitro, in vivo

Sep. 9, 2004

MB-06322 demonstrates activity in preclinical models of diabetes

Sep. 9, 2004

Therapeutic benefits of the PPAR agonist muraglitazar in diabetes

Sep. 9, 2004

First phase II Oxycyte protocol submitted

Sep. 9, 2004

Taisho and Arena identify potent MCH receptor antagonist ATC-0065

Sep. 9, 2004

Four series of PPAR modulators reported by Lilly

Sep. 9, 2004

S-21403 reported to reduce the effects of postprandial hyperglycemia in type 2 diabetes

Sep. 9, 2004

DPP-IV inhibitors effective in model of impaired glucose tolerance

Sep. 8, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 22, 2026.
‘Detargeted’ targeted gene therapy improves activity in Pompe
BioWorld
A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...
Roche reports new TREM2 agonists
BioWorld Science
F. Hoffmann-la Roche Ltd. and Hoffmann-La Roche Inc. have identified new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for...
Genescience presents STAT6 degrader for atopic dermatitis
BioWorld Science
Genescience Pharmaceutical Co. Ltd. has presented data on a new STAT6 PROTAC degrader – GenSciP166 – which selectively targets STAT6 for proteasomal degradation....
Unmasking the X: EPAC2 shifts the fragile X landscape
BioWorld
Researchers at UCLA have shown that divergent neuronal signaling in fragile X mice converges on EPAC2, a druggable target whose inhibition restores circuit...